Evidence map›Paper›PMID 28697727›Full record

ArticleBMC nephrology2017

Intermedin attenuates renal fibrosis by induction of heme oxygenase-1 in rats with unilateral ureteral obstruction.

Xi Qiao, Lihua Wang, Yanhong Wang, Xiaole Su, Yufeng Qiao, Yun Fan, Zhiqiang Peng

Open access · goldAbstract read
In one paragraph

Article in BMC nephrology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Xi QiaoDepartment of Nephrology, Second Hospital of Shanxi Medical University, Shanxi Kidney Disease Institute, 382, WuYi Road, Taiyuan, 030001, Shanxi, People's Republic of China. qiaoxi7347@126.com.
Lihua WangDepartment of Nephrology, Second Hospital of Shanxi Medical University, Shanxi Kidney Disease Institute, 382, WuYi Road, Taiyuan, 030001, Shanxi, People's Republic of China.
Yanhong WangDepartment of Microbiology and Immunology, Shanxi Medical University, 56, Xinjian Road, Taiyuan, 030001, Shanxi, People's Republic of China.
Xiaole SuDepartment of Nephrology, Second Hospital of Shanxi Medical University, Shanxi Kidney Disease Institute, 382, WuYi Road, Taiyuan, 030001, Shanxi, People's Republic of China.
Yufeng QiaoDepartment of Nephrology, Second Hospital of Shanxi Medical University, Shanxi Kidney Disease Institute, 382, WuYi Road, Taiyuan, 030001, Shanxi, People's Republic of China.
Yun FanDepartment of Nephrology, Second Hospital of Shanxi Medical University, Shanxi Kidney Disease Institute, 382, WuYi Road, Taiyuan, 030001, Shanxi, People's Republic of China.
Zhiqiang PengDepartment of Nephrology, Second Hospital of Shanxi Medical University, Shanxi Kidney Disease Institute, 382, WuYi Road, Taiyuan, 030001, Shanxi, People's Republic of China.
Second Hospital of Shanxi Medical University · CNShanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIntermedin [IMD, adrenomedullin-2 (ADM-2)] attenuates renal fibrosis by inhibition of oxidative stress. However, the precise mechanisms remain unknown. Heme oxygenase-1 (HO-1), an antioxidant agent, is associated with antifibrogenic effects. ADM is known to induce HO-1. Whether IMD has any effect on HO-1 is unclear. Herein, we determined whether the antifibrotic properties of IMD are mediated by induction of HO-1.

methodsRenal fibrosis was induced by unilateral ureteral obstruction (UUO) performed on male Wistar rats. Rat proximal tubular epithelial cell line (NRK-52E) was exposed to rhTGF-β1 (10 ng/ml) to establish an in vitro model of epithelial-mesenchymal transition (EMT). IMD was over-expressed in vivo and in vitro using the vector pcDNA3.1-IMD. Zinc protoporphyrin (ZnPP) was used to block HO-1 enzymatic activity. IMD effects on HO-1 expression in the obstructed kidney of UUO rat and in TGF-β1-stimulated NRK-52E were analyzed by real-time RT-PCR, Western blotting or immunohistochemistry. HO activity in the obstructed kidney, contralateral kidney of UUO rat and NRK-52E was examined by measuring bilirubin production. Renal fibrosis was determined by Masson trichrome staining and collagen I expression. Macrophage infiltration and IL-6 expression were evaluated using immunohistochemical analysis. In vivo and in vitro EMT was assessed by measuring α-smooth muscle actin (α-SMA) and E-cadherin expression using Western blotting or immunofluorescence, respectively.

resultsHO-1 expression and HO activity were increased in IMD-treated UUO kidneys or NRK-52E. The obstructed kidneys of UUO rats demonstrated significant interstitial fibrosis on day 7 after operation. In contrast, kidneys that were treated with IMD gene transfer exhibited minimal interstitial fibrosis. The obstructed kidneys of UUO rats also had greater macrophage infiltration and IL-6 expression. IMD restrained infiltration of macrophages and expression of IL-6 in UUO kidneys. The degree of EMT was extensive in obstructed kidneys of UUO rats as indicated by decreased expression of E-cadherin and increased expression of α-SMA. In vitro studies using NRK-52E confirmed these observations. EMT was suppressed by IMD gene delivery. However, all of the above beneficial effects of IMD were eliminated by ZnPP, an inhibitor of HO enzyme activity.

conclusionThis study demonstrates that IMD attenuates renal fibrosis by induction of HO-1.

Indexed as

AdrenomedullinAnimalsCells, CulturedEnzyme InductionFibrosisGene Transfer TechniquesHeme Oxygenase (Decyclizing)Kidney DiseasesMaleNeuropeptidesRandom AllocationRatsRats, WistarUreteral ObstructionAdm2 protein, ratAdrenomedullinHeme Oxygenase (Decyclizing)Hmox1 protein, ratNeuropeptidesFibrosisHeme oxygenase-1IntermedinReactive oxygen speciesRenal

Identifiers

PMID28697727
PMCPMC5505135
OpenAlexW2734496067

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.